The radical trial: Exploring combination therapies

Retina Today

Volumn , Issue JANUARY, 2008, Pages 59-62

  Hudson, Henry L ^a  

^a Retina Centers PC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 82055186248     PISSN: None     EISSN: 18250572     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Augustin AJ, Offerman I. Combination therapy for choroidal neovascularisation. Drugs Aging. 2007;24:979-990.
2. Kaiser P. Verteporfin photodynamic therapy and anti-angiogenic drugs: potential for combination therapy in exudative age-related macular degeneration. Curr Med Res Opin. 2007;23:477-487.
3. Spaide RF. Rationale for combination therapies for choroidal neovascularization. Am J Ophthalmol. 2006;141:149-156.
4. Rosenfeld PJ, Brown DM, Heier JS, et al; The MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419-1431.
5. Brown DM, Kaiser PK, Michels M, et al; The ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432-1444.
6. Lucentis (ranibizumab injection) prescribing information. San Francisco, California: Genentech; 2006. Available at: http://www.gene.com/gene/products/information/tgr/lucentis/ index.jsp. Accessed Jan. 14, 2006.
7. Eyetech Study Group. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology. 2003;110:979-986.
8. Heier JS, Boyer DS, Ciulla TA, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS study. Arch Ophthalmol. 2006;124:1532-1542.
9. Dhalla MS, Shah GK, Blinder KJ, Ryan EH Jr, Mittra RA, Tewari A. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Retina. 2006;26:988-993.
10. Augustin AJ, Puls S, Offermann I. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina. 2007;27:133-140.
11. Lazic R, Gabric N. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology. 2007;114:1179-1185.
12. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report 1. Arch Ophthalmol. 1999;117:1329-1345.
13. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-TAP report 2. Arch Ophthalmol. 2001;119:198-207.
14. Kaiser PK, Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group. Verteporfin therapy for subfoveal choroidal neovascularization in agerelated macular degeneration: 5-year results of two randomized clinical trials with an openlabel extension TAP report no. 8. Graefes Arch Clin Exp Ophthalmol. 2006;244:1132-1142.
15. Verteporfin In Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovasculariaation - Verteporfin In Photodynamic Therapy report 2. Am J Ophthalmol. 2001;131:541-560.
16. Miller JW, Walsh AW, Kramer M, et al. Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin. Arch Ophthalmol. 1995;113:810-818.
17. Kramer M, Miller JW, Michaud N, et al. Liposomal benzoporphyrin derivative verteporfin in photodynamic therapy: selective treatment of choroidal neovascularization in monkeys. Ophthalmology. 1996;103:427-438.
18. Visudyne in Minimally Classic Choroidal Neovascularization Study Group. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol. 2005;123:448-457.
19. Michels S, Hansmann F, Geitzenauer W, Schmidt-Erfurth U. Influence of treatment parameters on selectivity of verteporfin therapy. Invest Ophthalmol Vis Sci. 2006;47;371-376.
20. Stur M, VER Study Group. Verteporfin Early Retreatment (VER): 12-month results of a phase IIIb controlled clinical trial. Paper presented at: Annual Meeting of the Association for Research in Vision and Ophthalmology; April 27, 2004; Fort Lauderdale, Florida.
21. Schmidt-Erfurth U, Miller J, Sickenberg M, et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study. Arch Ophthalmol. 1999;117:1177-1187.
22. Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007;143:566-583.